BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, January 2, 2026
See today's BioWorld Asia
Home
» Upsher-Smith Nabs Proximagen in CVR-Based $555M Buyout
To read the full story,
subscribe
or
sign in
.
Upsher-Smith Nabs Proximagen in CVR-Based $555M Buyout
June 20, 2012
By
Nuala Moran
LONDON – Proximagen Group plc has fallen into the arms of its long-term partner and 16 percent shareholder, Upsher-Smith Laboratories Ltd., in a deal worth up to £356.8 million (US$554.7 million).
BioWorld Asia